Daniel Osula
Urology · Huntsville, ALNPI 1457770851
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 390 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,643, 6.7 times the $247 reported in 2020.
Across 390 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$1K
- Astellas Pharma US Inc$1K
- AbbVie$760
- Antares Pharma, Inc.$517
- Boston Scientific$459
- Endo Pharmaceuticals Inc.$440
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,56296%
- Education$2534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 66 | $1,197 |
| Astellas Pharma US Inc | 79 | $1,146 |
| AbbVie(2 entities) | 48 | $760 |
| Antares Pharma, Inc. | 29 | $517 |
| Boston Scientific | 15 | $459 |
| Endo Pharmaceuticals Inc. | 28 | $440 |
| Pfizer | 17 | $336 |
| Ferring Pharmaceuticals Inc. | 9 | $191 |
| Endo USA, Inc. | 9 | $174 |
| Urogen Pharma, Inc. | 8 | $170 |
| Halozyme Inc | 8 | $147 |
| Medtronic | 7 | $138 |
| Myriad Genetic Laboratories, Inc. | 7 | $114 |
| Myovant Sciences Inc. | 6 | $92 |
| Bayer | 4 | $84 |
| Accord Healthcare, Inc. | 4 | $73 |
| Dendreon Pharmaceuticals LLC | 2 | $72 |
| Tolmar Pharmaceuticals, Inc. | 3 | $69 |
| Johnson & Johnson | 3 | $64 |
| Olympus America Inc. | 3 | $61 |
| Telix Pharmaceuticals | 2 | $54 |
| Convatec Inc. | 3 | $49 |
| Coloplast | 2 | $48 |
| Verity Pharmaceuticals Inc. | 3 | $46 |
| Conmed Corporation | 2 | $41 |
| Mission Pharmacal Company | 2 | $38 |
| Travere Therapeutics, Inc. | 11 | $36 |
| Progenics Pharmaceuticals, Inc. | 2 | $36 |
| Hollister Incorporated | 1 | $30 |
| Rochester Medical Corporation | 1 | $24 |
| Merck | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Axonics, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LithoVue$231
How this compares
$6,815 in reported general payments places this provider in the 70th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 56 | $46,139 |
| GemtesaVibegron | 42 | $33,960 |
| XyostedTestosterone Enanthate | 13 | $7,703 |
| Tamsulosin Hcl | 449 | $6,374 |
| Tolterodine Tartrate ErTolterodine Tartrate | 31 | $4,476 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 77 | $3,081 |
| Estradiol | 38 | $3,049 |
| Finasteride | 229 | $2,659 |
| Testosterone Cypionate | 88 | $2,279 |
| Solifenacin Succinate | 46 | $1,616 |
| Cephalexin | 185 | $1,012 |
| Oxybutynin Chloride ErOxybutynin Chloride | 38 | $888 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $838 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 147 | $430 |
| Doxazosin Mesylate | 12 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,146 | $46,13956 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1,197 | $33,96042 claims |
| Antares Pharma, Inc.Xyosted | $517 | $7,70313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 179 urology providers in Alabama.
Other urology in Huntsville
- Jacob BrittHuntsville$14K
- Victor JiminezHuntsville$9K
- James FlattHuntsville$9K
- Joseph PettusHuntsville$7K
- Ryan BlackHuntsville$7K
- Thomas ChiBirmingham$463K
- Joel FunkBirmingham$347K
- Adam BaumgartenBirmingham$271K
- Brian ChristineHomewood$215K
- Vincent BivinsHomewood$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.